Deals: Page 72
-
Allergan acquires Anterios to enhance neurotoxin delivery, bolsters Botox portfolio
Anterios' platform enables Botox and other neurotoxins to be delivered through the skin, rather than by injection.
By Nicole Gray • Jan. 12, 2016 -
Seres signs on with Nestlé Health Science in gut drug partnership
The deal will make Nestlé Health Science the main partner for Seres outside of North America.
By Nicole Gray • Jan. 12, 2016 -
Walgreens' leadership defends unconventional Valeant deal
Walgreens' CEO expects the agreement with Valeant will help lower costs, comparing it to successful arrangements with pharmacies in Europe.
By Nicole Gray • Jan. 11, 2016 -
Shire buys Baxalta for $32 billion, ending months-long pursuit
After rejecting prior offers, Baxalta agreed to a stock and cash deal. Ireland-based Shire will gain Baxalta's hemophilia and rare-disease drug portfolio.
By Ned Pagliarulo • Jan. 11, 2016 -
Biotech Moderna partners with CRO to advance promising RNA therapies into trials
Since 2012, Moderna has raised $1 billion in venture funding for messenger RNA therapies. However, it has not yet tested any candidates in clinical trials.
By Nicole Gray • Jan. 11, 2016 -
Deal-hungry J&J partners with Chinese firm to focus on hep B breakthrough
Johnson & Johnson (J&J) is revealing details of 21 partnerships at this year's JP Morgan meeting.
By Nicole Gray • Jan. 8, 2016 -
Flurry of venture deals hits biopharma ahead of JPMorgan healthcare conference
J&J, Roche, Amgen Ventures, and Abbvie have all stepped into new collaborations with several venture biopharma firms.
By Ned Pagliarulo • Jan. 7, 2016 -
In efficiency bid, Novartis selling Alcon unit to Recipharm in $20M deal
Recipharm will expand its presence in France—one of its seven key operational regions.
By Nicole Gray • Jan. 7, 2016 -
Biogen partners with Rodin on Alzheimer's research, possible buy-out opp
Under the terms of the deal, Biogen has the right to acquire Rodin for $485 million.
By Nicole Gray • Jan. 7, 2016 -
Major Chinese pharma firm plots a $3 billion IPO in Hong Kong
The IPO could happen sometime in the third quarter, and would be the largest healthcare IPO on Hong Kong's exchange.
By Nicole Gray • Jan. 5, 2016 -
Baxalta strikes a $1.6B immuno-oncology deal ahead of potential Shire deal
The deal with Symphogen covers six early-stage drugs.
By Nicole Gray • Jan. 5, 2016 -
Deep Dive
The year ahead: 11 execs & experts predict what's in store for biopharma in 2016
With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.
By Nicole Gray • Jan. 4, 2016 -
WellCare ditches UnitedHealth in PBM scuffle, opts for CVS
The switch became effective on January 1, shifting WellCare's 3.8 million members onto CVS Health Corp's network.
By Nicole Gray • Jan. 4, 2016 -
In unique Valeant-Walgreens distribution deal, drugmaker to retain titles to its therapies
As part of the deal, Valeant will take a $150 million revenue hit.
By Nicole Gray • Dec. 23, 2015 -
Baxalta fielding buyout offers, but may land with Shire after all
Shire has renewed its push to acquire Baxalta, adding cash into a previous all-stock offer, according to Reuters.
By Nicole Gray • Dec. 23, 2015 -
Deep Dive
11 biopharma execs & experts look back on 2015: A record year for record-breaking
We spoke with bigwigs from Sanofi, the Biosimilars Council, Novocure, Accenture, Bain, amfAR, Boehringer Ingelheim, and more on what they considered the most significant events that drove biopharma this past year.
By Nicole Gray • Dec. 22, 2015 -
Bayer pumping 335 million euros into CRISPR Therapeutics gene-editing partnership
Bayer plans to research how to bring the gene-editing mechanism to target cells.
By Nicole Gray • Dec. 22, 2015 -
Bristol-Myers spinning off its entire HIV pipeline to Glaxo for $1.5 billion
The deal is technically two separate agreements: one for Bristol-Myers' late stage HIV assets, and a second for a number of preclinical HIV drugs.
By Ned Pagliarulo • Dec. 18, 2015 -
Shire-Baxalta takeover drama barreling towards its final act
Baxalta rejected Shire's initial $30.6 billion offer six months ago, and has spurned further attempts twice since then. But the end may be in sight.
By Nicole Gray • Dec. 18, 2015 -
University of California invests $250 million in biotech venture fund
The fund will be run by Silicon Valley entrepreneur Vivek Ranadivé.
By Nicole Gray • Dec. 18, 2015 -
Gilead snags 15% stake in Galapagos 3 months after AbbVie backs out
Under the deal, the firms will work together to develop and commercialize filogotinib for rheumatoid arthritis (RA).
By Nicole Gray • Dec. 18, 2015 -
With eye on the future, AstraZeneca to beef up manufacturing, R&D presence in China
Investing directly in manufacturing and R&D capabilities in the country is seen as critical for future drug approvals in the market.
By Nicole Gray • Dec. 17, 2015 -
Amgen to snatch 3 drugs back from Glaxo in key int'l markets
The company will reacquire the sales rights to the drugs in 48 countries.
By Nicole Gray • Dec. 16, 2015 -
Boehringer, Sanofi prepping complex asset swap of consumer, animal health units
The $20 billion deal is expected to close in Q4 2016.
By Nicole Gray • Dec. 15, 2015 -
Akebia strikes $350 million deal with Mitsubishi Tanabe for next-gen anemia pill
Vadadustat is in phase 3 trials for treatment of non-dialysis chronic kidney disease (CKD).
By Nicole Gray • Dec. 15, 2015
Previous
